Esomeprazole: potent acid suppression in the treatment of acid-related disorders

References

• Dent J, Brun J, Fendrick AM et al. An evidence-based appraisal of reflux disease management – the Genval Workshop Report. Gut 44(Suppl. 2), 1–26 (1999).
   PubMed Web of Science ®Google Scholar
• Hollenz M, Stolte M, Labenz J. Prevalence of gastro-oesophageal reflux disease in general practice. Dtsch Med. Wochenschr 127, 1007–1012 (2003).
   Google Scholar
• Klauser AG, Schindlbeck NE, Muller-Lissner SA. Symptoms in gastro-oesophageal reflux disease. Lancet 335, 205–208 (1990).
   PubMed Web of Science ®Google Scholar
• Kulig M, Leodolter A, Vieth M et al. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease – an analysis based on the ProGERD initiative. Aliment Pharmacol. Ther.18,767–776 (2002).
   Google Scholar
• Olbe L, Carlsson E, Lindberg P. A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nature Rev. Drug Discov.2, 132–239 (2003).
   PubMedGoogle Scholar
• Hutt A, Tan S. Drug chirality and its clinical significance. Drugs 52(Suppl. 5), 1–22 (1996).
   PubMedGoogle Scholar
• Cahn RS, Ingold CK, Prelog V. Angew. Chem. 78, 413–447 (1966).
   Google Scholar
• Äbelö A, Andersson TB, Antonsson M, Naudot AK, Skanberg I, Weidolf L. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab. Dispos.28,966–972 (2000).
   PubMed Web of Science ®Google Scholar
• Shin JM, Besancon M, Bamberg K, Sachs G. Structural aspects of the gastric H,K ATPase. Ann. NY Acad. Sci. 834, 65–66 (1997).
   PubMed Web of Science ®Google Scholar
• Huang JQ, Hunt RH. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician. Best Pract. Res. Clin. Gastro. 15, 355–370 (2001).
   PubMed Web of Science ®Google Scholar
• Zimmermann AE. Esomeprazole: a novel proton pump inhibitor for the treatment of acid-related disorders. Formulary 35, 882–893 (2000).
   Google Scholar
• Langtry HD, Wilde MI. Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs. Drugs 56, 447–486 (1998).
   PubMed Web of Science ®Google Scholar
• Lindberg P, Brandstrom A, Wallmark B, Mattsson H, Rikner L, Hoffmann KJ. Omeprazole: the first proton pump inhibitor. Med. Res. Rev. 10, 1–24 (1990).
   PubMed Web of Science ®Google Scholar
• Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J. Biol. Chem. 272, 22438–22446 (1997).
   PubMed Web of Science ®Google Scholar
• Fellenius E, Berglindh T, Sachs G et al. Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ K+)ATPase. Nature 290, 159–161 (1981).
   PubMed Web of Science ®Google Scholar
• Petersen KU. Comparison of different proton pump inhibitors. In: Proton Pump Inhibitors. Olbe L (Ed.), Birkhäuser, Basel, Switzerland, 143–157 (1999).
   Google Scholar
• Li XQ, Andersson TB, Ahlstrom M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab. Dispos.32,821–827 (2004).
   PubMed Web of Science ®Google Scholar
• Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin. Pharmacokinet. 31, 9–28 (1996).
   PubMed Web of Science ®Google Scholar
• Holloway RH, Dent J, Narielvala F, Mackinnon AM. Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis. Gut38, 649–654 (1996).
   PubMed Web of Science ®Google Scholar
• Andersson T, Hassan-Alin M, Hasselgren G, Rohss K, Weidolf L. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin. Pharmacokinet. 40, 411–426 (2001).
   PubMed Web of Science ®Google Scholar
• Andersson T, Rohss K, Bredberg E, Hassan-Alin M. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment. Pharmacol. Ther.15,1563–1569 (2001).
   PubMed Web of Science ®Google Scholar
• Lind T, Cederberg C, Ekenved G, Haglund U, Olbe L. Effect of omeprazole – a gastric proton pump inhibitor – on pentagastrin stimulated acid secretion in man. Gut24, 270–276 (1983).
   PubMed Web of Science ®Google Scholar
• Junghard O, Hassan-Alin M, Hasselgren G. The effect of the area under the plasma concentration vs. time curve and the maximum plasma concentration of esomeprazole on intragastric pH. Eur. J. Clin. Pharmacol.58, 453–458 (2002).
   PubMed Web of Science ®Google Scholar
• Nexium®. Wilmington (DE): AstraZeneca LP, (2003).
   Google Scholar
• Hassan-Alin M, Niazi M, Röhss K, Lngerstrom PO. Esomeprazole, the S-isomer of omeprazole is optically stable in humans. Gastroenterology 118, A1244 (2000).
   Google Scholar
• Hassan-Alin M, Andersson T, Bredberg E, Rohss K. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur. J. Clin. Pharmacol. 56, 665–670 (2000).
   PubMed Web of Science ®Google Scholar
• Hassan-Alin M, Andersson T, Niazi M, Rohss K. A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects. Eur. J. Clin. Pharmacol.60, 779–784 (2005).
   PubMed Web of Science ®Google Scholar
• Katz PO, Castell DO, Chen Y, Andersson T, Sostek MB. Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study. Aliment. Pharmacol. Ther. 20, 399–406 (2004).
   PubMed Web of Science ®Google Scholar
• Lind T, Rydberg L, Kyleback A et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. 14, 861–867 (2000).
   PubMed Web of Science ®Google Scholar
• Sotaniemi EA, Arranto AJ, Pelkonen O, Pasanen M. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin. Pharmacol. Ther.61,331–339 (1997).
   PubMed Web of Science ®Google Scholar
• Breuel HP, Hartmann M, Bondy S. Pantoprazole in the elderly: no dose-adjustment. Gut(Suppl. 4), 77 (1994).
   Google Scholar
• Flouvat B, Delhotal-Landes B, Cournot A, Dellatolas F. Single and multiple dose pharmacokinetics of lansoprazole in elderly subjects. Br. J. Clin. Pharmacol.36,467–469 (1993).
   PubMed Web of Science ®Google Scholar
• Landahl S, Andersson T, Larsson M et al. Pharmacokinetic study of omeprazole in elderly healthy volunteers. Clin. Pharmacokinet.23, 469–476 (1992).
   PubMedGoogle Scholar
• Hasselgren G, Hassan-Alin M, Andersson T, Clar-Nilsson C, Rohss K. Pharmacokinetic study of esomeprazole in the elderly. Clin. Pharmacokinet.40, 145–150 (2001).
   PubMed Web of Science ®Google Scholar
• Rodighiero V. Effects of liver disease on pharmacokinetics. An update. Clin. Pharmacokinet.37, 399–331 (1999).
   PubMed Web of Science ®Google Scholar
• Andersson T, Olsson R, Regardh CG, Skanberg I. Pharmacokinetics of [14c]omeprazole in patients with liver cirrhosis. Clin. Pharmacokinet.24, 71–78 (1993).
   PubMedGoogle Scholar
• Rinetti M, Regazzi MB, Villani P, Tizzoni M, Sivelli R. Pharmacokinetics of omeprazole in cirrhotic patients. Arzneimittelforschung 41, 420–422 (1991).
   PubMedGoogle Scholar
• Coste T, Logeais C, Delhotal-Landes B, Dellatolas F, Lemiare M, Rautureau J. Pharmacokinetics of lansoprazole after repreated administration in cirrhosis patients. Gastroenterology 104(Suppl.), A59 (1993).
   Google Scholar
• Kirsch RE, Hawarden D, Theron I, Venter JL, Hartmann M, Lahmann R. Pharmacokinetics of pantoprazole in patients with liver insufficienc due to chronic hepatitis. Gastroenterology 116, A216 (1999) (Abstract).
   Google Scholar
• Hoyumpa AM, Trevino-Alanis H, Grimes I, Humphries TJ. Rabeprazole: pharmacokinetics in patients with stable, compensated cirrhosis. Clin. Ther.21,691–701 (1999).
   PubMedGoogle Scholar
• Sjovall H, Bjornsson E, Holmberg J, Hasselgren G, Rohss K, Hassan-Alin M. Pharmacokinetic study of esomeprazole in patients with hepatic impairment. Eur. J. Gastroenterol. Hepatol.14,491–496 (2002).
   PubMed Web of Science ®Google Scholar
• Wilder-Smith CH, Bondarov P, Lundgren M et al. Intravenous esomeprazole (40 mg and 20 mg) inhibits gastric acid secretion as effectively as oral esomeprazole: results of two randomized clinical studies. Eur. J. Gastroenterol. Hepatol.17,191–197 (2005).
   PubMed Web of Science ®Google Scholar
• Röhss K, Bondarov P, Lundin C, Nilsson-Pieschl C, Nyman L. Esomeprazole 40 mg administered as a 30-minute intravenous infusion provides the same effective acid control as oral administration in healthy subjects. Gut 52(Suppl. VI), A130 (2003).
   Google Scholar
• Keating GM, Figgitt DP. Intravenous esomeprazole. Drugs 64, 875–882 (2004).
   PubMed Web of Science ®Google Scholar
• Wilder-Smith CH, Rohss K, Bondarov P, Hallerback B, Svedberg LE, Ahlbom H. Esomeprazole 40 mg iv. provides faster and more effective intragastric acid control than pantoprazole 40 mg iv.: results of a randomized study. Aliment. Pharmacol. Ther.20, 1099–1104 (2004).
   PubMed Web of Science ®Google Scholar
• Lindberg P, Keeling D, Fryklund J, Andersson T, Lundborg P, Carlsson E. Review article: esomeprazole-enhanced bio-availability, specificity for the proton pump and inhibition of acid secretion. Aliment. Pharmacol. Ther. 17, 481–488 (2003).
   PubMed Web of Science ®Google Scholar
• Hunt RH. Importance of pH control in the management of GERD. Arch. Intern. Med. 159, 649–657 (1999).
   Google Scholar
• Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 51(Suppl. 1), 59–67 (1992).
   PubMed Web of Science ®Google Scholar
• Miner P Jr, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am. J. Gastroenterol.98(12), 2616–2620 (2003).
   PubMedGoogle Scholar
• Wilder-Smith CH, Rohss K, Nilsson-Pieschl C, Junghard O, Nyman L. Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers. Digestion 68, 184–188 (2003).
   PubMed Web of Science ®Google Scholar
• Röhss K, Lind T, Wilder-Smith C. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. Eur. J. Clin. Pharmacol. 60, 531–539 (2004).
   PubMed Web of Science ®Google Scholar
• Wilder-Smith CH, Lind T, Lundin C. Comparison of esomeprazole (20, 40, 80 mg) versus lansoprazole (15, 30, 60 mg) on intragastric pH in healthy subjects. Gastroenterology 124, A44 (2003).
   Google Scholar
• Armstrong D, Bair D, James C, Tanser L, Escobedo S, Nevin K. Oral esomeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects. Aliment. Pharmacol. Ther.18, 705–711 (2003).
   PubMed Web of Science ®Google Scholar
• Miehlke S, Madisch A, Kirsch C et al. Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily – a randomized, two-way crossover study. Aliment. Pharmacol. Ther. 21, 963–967 (2005).
   PubMed Web of Science ®Google Scholar
• Röhss K, Hasselgren G, Hedenstrom H. Effect of esomeprazole 40 mg vs. 14 comeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. Dig. Dis. Sci.47,954–958 (2002).
   PubMed Web of Science ®Google Scholar
• Galmiche JP, Sacher-Huvelin S, Bruley des Varannes S et al. A comparative study of the early effects of tenatoprazole 40 mg and esomeprazole 40 mg on intragastric pH in healthy volunteers. Aliment. Pharmacol. Ther. 21, 575–582 (2005).
   PubMed Web of Science ®Google Scholar
• Hammer J, Schmidt B. Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough. Aliment. Pharmacol. Ther. 19, 1105–1110 (2004).
   PubMed Web of Science ®Google Scholar
• Katz PO, Castell DO, Levine D. Esomeprazole resolves chronic heartburn in patients without erosive oesophagitis. Aliment. Pharmacol. Ther. 18, 875–882 (2003).
   PubMed Web of Science ®Google Scholar
• Armstrong D, Talley NJ, Lauritsen K et al. The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole. Aliment. Pharmacol. Ther. 20, 413–421 (2004).
   PubMed Web of Science ®Google Scholar
• Castell DO, Kahrilas PJ, Richter JE et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am. J. Gastroenterol.97,575–583 (2002).
   PubMed Web of Science ®Google Scholar
• Kahrilas PJ, Falk GW, Johnson DA et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment. Pharmacol. Ther.14, 1249–1258 (2000).
   PubMed Web of Science ®Google Scholar
• Richter JE, Kahrilas PJ, Johanson J et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am. J. Gastroenterol.96,656–665 (2001).
   PubMed Web of Science ®Google Scholar
• Labenz J, Armstrong D, Lauritsen K et al. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. Aliment. Pharmacol. Ther.21, 739–746 (2005).
   PubMed Web of Science ®Google Scholar
• Lundell LR, Dent J, Bennett JR et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut45,172–180 (1999).
   PubMed Web of Science ®Google Scholar
• Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 117, 11–16 (1999).
   PubMed Web of Science ®Google Scholar
• Gillessen A, Beil W, Modlin IM, Gatz G, Hole U. 40 mg pantoprazole and 40 mg esomeprazole are equivalent in the healing of esophageal lesions and relief from gastroesophageal reflux disease-related symptoms. J. Clin. Gastroenterol.38,332–340 (2004).
   PubMed Web of Science ®Google Scholar
• Howden CW, Ballard ED II, Robieson W. Evidence for therapeutic equivalence of lansoprazole 30 mg and esomeprazole 40 mg in the treatment of erosive esophagitis. Clin. Drug Invest.22,99–109 (2002).
   PubMed Web of Science ®Google Scholar
• Scholten T, Gatz G, Hole U. Once-daily pantoprazole 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD-related symptoms. Aliment. Pharmacol. Ther.18, 587–594 (2003).
   PubMedGoogle Scholar
• Fennerty MB, Johanson JF, Hwang C, Sostek M. Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis. Aliment. Pharmacol. Ther.21(4), 455–463 (2005).
   PubMedGoogle Scholar
• DeVault KR, Castell DO, American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am. J. Gastroenterol.100,190–200 (2005).
   PubMed Web of Science ®Google Scholar
• Klauser AG, Schindlbeck NE, Muller-Lissner SA. Symptoms in gastro-oesophageal reflux disease. Lancet 335, 205–208 (1990).
   PubMed Web of Science ®Google Scholar
• Johnsson F, Hatlebakk JG, Klintenberg AC et al. One-week esomeprazole treatment: an effective confirmatory test in patients with suspected gastroesophageal reflux disease. Scand. J. Gastroenterol.38,354–359 (2003).
   PubMed Web of Science ®Google Scholar
• Numans ME, Lau J, de Wit NJ, Bonis PA. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann. Intern. Med.140,518–527 (2004).
   PubMed Web of Science ®Google Scholar
• Vakil NB, Shaker R, Johnson DA et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment. Pharmacol. Ther. 5, 927–935 (2001).
   Google Scholar
• Johnson DA, Benjamin SB, Vakil NB et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am. J. Gastroenterol.96,27–34 (2001).
   PubMed Web of Science ®Google Scholar
• Lasuritsen K, Deviere J, Bigard MA et al. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. Aliment. Pharmacol. Ther. 17, 333–341 (2003).
   PubMedGoogle Scholar
• Labenz J, Armstrong D, Katelaris PH, Schmidt S, Adler J, Eklund S. A comparison of esomeprazole and pantoprazole for maintenance treatment of healed erosive esophagitis. Gut 53(Suppl. VI), A108 (2004).
   Google Scholar
• Talley NJ, Lauritsen K, Tunturi-Hihnala H et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of ‘on-demand’ therapy for 6 months. Aliment. Pharmacol. Ther. 15, 347–354 (2001).
   PubMed Web of Science ®Google Scholar
• Talley NJ, Venables TL, Green JR et al. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months. Eur. J. Gastroenterol. Hepatol.14,857–863 (2002).
   PubMed Web of Science ®Google Scholar
• Tsai HH, Chapman R, Shepherd A et al. Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND Study. Aliment. Pharmacol. Ther.20, 657–665 (2004).
   PubMed Web of Science ®Google Scholar
• Bytzer P, Blum AL. Personal view: rationale and proposed algorithms for symptom-based proton pump inhibitor therapy for gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther.20, 389–398 (2004).
   PubMed Web of Science ®Google Scholar
• DeVault KR, Liu S, Hoyle P, Sostel M. Esomeprazole 20 mg versus lansoprazole 15 mg for maintenance of healing of erosive esophagitis. Am. J. Gastroenterol.99, S6–S7 (2004).
   PubMedGoogle Scholar
• Koop H, Schepp W, Muller-Lissner S et al. Consensus conference of the DGVS on gastroesophageal reflux. Z Gastroenterol. 43, 163 (2005).
   Google Scholar
• Wahlqvist P, Junghard O, Higgins A, Green J. Cost effectiveness of esomeprazole compared with omeprazole in the acute treatment of patients with reflux oesophagitis in the UK. Pharmacoeconomics 20, 279–287 (2002).
   PubMedGoogle Scholar
• Wahlqvist P, Junghard O, Higgins A, Green J. Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies. Pharmacoeconomics 20, 267–277 (2002).
   PubMed Web of Science ®Google Scholar
• Wahlqvist P. In Finland, Sweden and the UK, esomeprazole is cost-effective compared with omeprazole for the acute treatment of patients with reflux esophagitis. Value Health 3, 358 (2000).
   Google Scholar
• Jaspersen D, Kulig M, Labenz J et al. Prevalence of extra-oesophageal manifestations in gastro-oesophageal reflux disease: an analysis based on the ProGERD Study. Aliment. Pharmacol. Ther.17, 1515–1520 (2003).
   PubMed Web of Science ®Google Scholar
• Nord HJ. Extraesophageal symptoms: what role for the proton pump inhibitors? Am. J. Med. 117(Suppl. 5A), 56–62 (2004).
   Google Scholar
• Harding S. Efficacy of esomeprazole 40 mg twice daily for 16 weeks in adults with asthma: a randomized placebo-controlled trial. Gastroenterology (2005) (In Press).
   Google Scholar
• Malfertheiner P, Megraud F, O’Morain C et al. Current concepts in the management of Helicobacter pylori infection-the Maastricht 2–2000 Consensus Report. Aliment. Pharmacol. Ther.16, 167–180 (2002).
   Web of Science ®Google Scholar
• Tulassay Z, Kryszewski A, Dite P et al. One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease. Eur. J. Gastroenterol. Hepatol.13,1457–1465 (2001).
   PubMed Web of Science ®Google Scholar
• Veldhuyzen Van Zanten S, Lauritsen K et al. One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease. Aliment. Pharmacol. Ther.14, 1605–1611 (2000).
   PubMed Web of Science ®Google Scholar
• Lind T, Veldhuyzen van Zanten S et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter 1, 138–144 (1996).
   PubMedGoogle Scholar
• Lind T, Megraud F, Unge P et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 116, 248–253 (1999).
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Bayerdorffer E, Diete U et al. The GU-MACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Aliment. Pharmacol. Ther.13,703–712 (1999).
   PubMed Web of Science ®Google Scholar
• Veldhuyzen van Zanten S, Bradette M, Farley A, Leddin D, Lind T, Unge P. The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. Aliment. Pharmacol. Ther.13, 289–295 (1999).
   PubMedGoogle Scholar
• Megraud F, Lehn N, Lind T et al. Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study. Antimicrob. Agents Chemother.43, 2747–2752 (1999).
   PubMed Web of Science ®Google Scholar
• Wolle K, Leodolter A, Malfertheiner P, Konig W. Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000. J. Med. Microbiol. 51, 705–709 (2002).
   PubMed Web of Science ®Google Scholar
• Meyer JM, Silliman NP, Wang W et al. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993–2999. Ann. Intern. Med. 136(1), 13–24 (2002).
   Google Scholar
• Dore MP, Leandro G, Realdi G, Sepulveda AR, Graham DY. Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig. Dis. Sci. 45(1), 68–76 (2000).
   PubMedGoogle Scholar
• van der Wouden EJ, Thijs JC, van Zwet AA, Sluiter WJ, Kleibeuker JH. The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti Helicobacter pylori regimens: a meta-analysis. Am. J. Gastroenterol.7, 1751–1759 (1999).
   Google Scholar
• Miehlke S, Schneider-Brachert W, Bastlein E et al. Esomeprazole-based one-week triple therapy with clarithromycin and metronidazole is effective in eradicating Helicobacter pylori in the absence of antimicrobial resistance. Aliment. Pharmacol. Ther. 18, 799–804 (2003).
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Pajares JM. Esomeprazole-based therapy in Helicobacter pylori eradication: a meta-analysis. Dig. Liver Dis. 36, 253–259 (2004).
   Google Scholar
• Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N. Engl. J. Med. 340, 1888–1899 (1999).
   PubMed Web of Science ®Google Scholar
• Dubois RW, Melmed GY, Henning JM, Laine L. Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. Aliment. Pharmacol. Ther. 19, 197–208 (2004).
   PubMed Web of Science ®Google Scholar
• Rostom A, Dube C, Wells G et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst. Rev.4(CD002296) (2002).
   Google Scholar
• Goldstein JL. The comparative healing of gastric ulcers with esomeprazole versus ranitidine in patients taking either continuous COX2 selective NSAIDs or nonselective NSAIDs. Gastroenterology 126(4), A608 (Abstract).
   Google Scholar
• Yeomans N. An evidence-based analysis of esomeprazole therapy versus placebo for the prevention of gastric or duodenal ulcers in at-risk continuous NSAID users. Gastroenterology 124(4), A608 (abstract)
   Google Scholar
• Hawkey C, Talley NJ, Yeomans ND et al. Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal anti-inflammatory drugs, including selective COX-2 inhibitors. Am. J. Gastroenterol.100(5), 1028–1026 (2004).
   Google Scholar
• Goldstein JL, Miner PB, Schlesinger PK, Liu S, Silberg DG. Intragastric acid control in nonsteroidal anti-inflammatory drug (NSAID) users: comparison of esomeprazole, lansoprazole, and pantoprazole. Gastroenterology 128(Suppl. 2), A241 (Abstract).
   Google Scholar
• Chan FK, Ching JY, Hung LC et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N. Engl. J. Med.352,238–244 (2005).
   PubMed Web of Science ®Google Scholar
• AstraZeneca, data on file 1010.
   Google Scholar
• Maton PN, Vakil NB, Levine JG et al. Safety and efficacy of long-term esomeprazole therapy in patients with healed erosive oesophagitis. Drug Saf.24,625–635 (2001).
   PubMed Web of Science ®Google Scholar
• Creutzfeldt W. Risk-benefit assessment of omeprazole in the treatment of gastrointestinal disorders. Drug Saf.10,66–72 (1994).
   PubMed Web of Science ®Google Scholar
• Genta RM, Rindi G, Fiocca R, Magner DJ, D’Amico D, Levine DS. Effects of 6–22 months of esomeprazole treatment on the gastric mucosa. Am. J. Gastroenterol.98,1257–1265 (2003).
   PubMedGoogle Scholar
• Hasselgren B, Claar-Nilsson C, Hasselgren C, Niazi M, Svernhage E. Studies in healthy volunteers do not show any electrocardiographic effects with esomeprazole. Clin. Drug Invest.20,425–431 (2000).
   Web of Science ®Google Scholar
• Andersson T, Hassan-Alin M, Hasselgren G, Röhss K. Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole. Clin. Pharmacokinet.40,523–537 (2001).
   PubMed Web of Science ®Google Scholar
• AstraZeneca. Summary of Product Characteristics: Nexium® tablets 20 mg and 40 mg. 10 March, 2000.
   Google Scholar
• Takahashi K, Motohashi H, Yonezawa A et al. Lansoprazole-tacrolimus interaction in Japanese transplant recipient with CYP2C19 polymorphism. Ann. Pharmacother.38,791–794 (2004).
   PubMedGoogle Scholar
• Severino G, Chillotti C, De Lisa R, Del Zompo M, Ardau R. Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors. Ann. Pharmacother.39,162–164 (2005).
   PubMed Web of Science ®Google Scholar
• Labenz J, Petersen KU, Rosch W, Koelz HR. A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole. Aliment. Pharmacol. Ther.7,1015–1019 (2003).
   Google Scholar
• Luciani F, Spada M, De Milito A et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J. Natl Cancer Inst. 96, 1702–1713 (2004).
   PubMed Web of Science ®Google Scholar